drugset / Trial / NCT01675661

Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

NCT01675661

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).

Timeline

Start
2014-01
Primary completion
2015-07
Completion
2015-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 1200 mg

Indications